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Abstract
Objective
Although milder forms of HIV-associated neurocognitive disorder (HAND) remain prevalent,
a correlation to neuronal injury has not been established in patients on antiretroviral therapy
(ART). We examined the relationship between mild HAND and CSF neurofilament light pro-
tein (NFL), a biomarker of neuronal injury; and CSF neopterin, a biomarker of CNS immu-
noactivation, in virally suppressed patients on antiretroviral therapy (ART).
Design and Methods
We selected 99 subjects on suppressive ART followed longitudinally from the CNS HIV
Anti-Retroviral Therapy Effects Research (CHARTER) study. Based on standardized com-
prehensive neurocognitive performance (NP) testing, subjects were classified as neurocog-
nitively normal (NCN; n = 29) or impaired (NCI; n = 70). The NCI group included subjects
with asymptomatic (ANI; n = 37) or mild (MND; n = 33) HAND. CSF biomarkers were ana-
lyzed on two occasions.
Results
Geometric mean CSF neopterin was 25% higher in the NCI group (p = 0.04) and NFL and
neopterin were significantly correlated within the NCI group (r = 0.30; p<0.001) but not in the
NCN group (r = -0.13; p = 0.3). Additionally, a trend towards higher NFL was seen in the NCI
group (p = 0.06).
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Conclusions
Mild HAND was associated with increased intrathecal immune activation, and the correla-
tion between neopterin and NFL found in NCI subjects indicates an association between
neurocognitive impairment, CNS inflammation and neuronal damage. Together these find-
ings suggest that NCI despite ART may represent an active pathological process within the
CNS that needs further characterization in prospective studies.
Introduction
With antiretroviral therapy (ART) the incidence of HIV-associated dementia (HAD), the most
severe form of HIV-associated neurocognitive disorders (HAND), has been dramatically
reduced [1, 2]. However, despite this clear effect on more severe CNS disease, a number of
studies have reported a substantial prevalence of mainly the milder HAND forms asymptom-
atic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND) ranging from
18% to as high as 35–69% [2–5]. The formal diagnosis of HAND utilizes neuropsychological
testing in comparison to normative controls [3]. However, neuropsychological testing does not
distinguish between impairment resulting from ongoing brain injury or from static residual
damage due to prior events, a distinction that has important implications for therapeutic strat-
egies. CSF biomarkers that reflect processes within the brain constitute an important comple-
mentary approach to evaluate ongoing CNS disease as well as responses to ART [6, 7].
The light subunit of the neurofilament protein (NFL) is a major structural element of mye-
linated axons, and NFL concentration in CSF is a sensitive marker of neuronal damage in sev-
eral neurologic diseases[8–10]. In HIV-1 disease, CSF NFL levels are substantially increased in
patients with HAD [11, 12], but decreases and are frequently normalized with initiation of
ART. CSF neopterin is a marker of macrophage and microglial activation. While ART gener-
ally reduces immune activation, many patients still have residual immune activation in the
CNS despite viral suppression, and CSF neopterin frequently remains elevated even in patients
on long-term effective therapy [13, 14].
Although the clinical relevance of the milder forms of HAND, particularly ANI, has been
questioned [15, 16], recent data have suggested an increased risk of progression to symptom-
atic impairment in subjects diagnosed with ANI compared to neurocognitively unimpaired
subjects, supporting the value of an ANI diagnosis in the clinical setting [17]. However, it is not
fully established whether or not progression in neurocognitive impairment represents an ongo-
ing pathologic process within the CNS that continues even in the face of functioning ART.
Although residual inflammatory activity in the CNS is present in many virally suppressed
patients, the clinical significance of continuous low level intrathecal immune activation during
effective ART remains unclear. The aims of the current study were to investigate if milder
forms of HAND (ANI and MND) were associated with CSF markers of neuronal damage
(NFL) and immune activation (neopterin) despite effective viral suppression, and if CSF bio-
markers were associated with disease progression in patients with neurocognitive impairment.
Methods
Study design and subjects
We identified subjects from longitudinal neuroAIDS studies at the HIV Neurobehavioral
Research Program (HNRP), including the CNS HIV Anti-Retroviral Therapy Effects Research
(CHARTER) study, an ongoing observational multicenter cohort study which has been
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described in detail previously [2]. Individual subjects who were selected for inclusion in the cur-
rent analysis were all on combination antiretroviral therapy with viral suppression in plasma
(HIV-1 RNA<50 copies/ml at inclusion), had available stored samples of plasma and CSF, com-
prehensive neuropsychological assessments, and had no significant comorbidities (e.g., current
substance dependence, cerebrovascular disease, severe psychiatric or neurological disorders) that
would have a confounding impact on neurocognitive performance or CSF biomarkers. For the
purpose of the current analysis, subjects were classified as neurocognitively normal (NCN) or
neurocognitively impaired (NCI), based on results from neuropsychological (NP) testing using
normative adjustments and assessing seven cognitive domains. Overall cognitive status was
determined using the Global Deficit Score (GDS) approach, which gives greater weight to
impaired performance, as would be done by a clinician, and has been shown to be sensitive to
HIV-related impairments [18, 19]. Change in neurocognitive performance was determined in
relation to published normative standards as described previously [20, 21]. The NCI group con-
tained subjects diagnosed with either ANI or MND according to the Frascati criteria [3].
Although MND requires minor interference in daily functioning, subjects with ANI and MND
otherwise demonstrate identical degrees of impairment in NP-testing, and were collectively com-
pared to unimpaired subjects in the current analysis. Subjects were examined on two separate
occasions to allow evaluation of the NP-stability and change in CSF biomarkers over time, and
were selected to yield approximately a 2:1 sample of patients with NCI vs. NCN, with a roughly
equal distribution of subjects with ANI or MND within the NCI group. In addition, to evaluate
an association between the CSF biomarkers and longitudinal NP decline, subjects with NCI were
selected to include individuals with either stable or declining neurocognitive performance.
Study procedures
Subjects included from the longitudinal studies underwent a venipuncture, lumbar puncture
(LP), neurological assessment, comprehensive neurocognitive testing, detailed substance use
history, a fully-structured psychiatric interview for lifetime and current (30-day) diagnoses of
major depression and alcohol and other psychoactive substance use disorders, and a measure
of mood symptoms in the previous fourteen days. Details of the assessments, including assess-
ment of comorbidities, have been reported in detail previously [2, 17].
Data collection for the study was approved by the UCSD Human Research Protection Pro-
gram (# 110089), and all study participants provided written informed consent. De-identified
data and biological samples were obtained with the permission of the CHARTER steering com-
mittee and HNRP Research Review Committee.
Laboratory methods
Clinical laboratory assessments of CSF WBC and CD4+ T-lymphocyte count were per-
formed at each participating site. Plasma and CSF HIV-1 RNA was quantified using RT-PCR
(Amplicor1 version 1.5, Roche Diagnostic Systems) with a lower limit of quantification of
50 copies/ml.
For CSF biomarker analysis, we used cell-free specimens of CSF stored at -80°C and not
thawed until analysis. CSF NFL was measured using a sandwich ELISA method with a lower
limit of quantification of 50 ng/l (NF-light1 ELISA kit, UmanDiagnostics AB, Umeå, Sweden)
at the Clinical Neurochemistry Laboratory at the University of Gothenburg according to the
manufacturers description. CSF NFL concentrations have previously been shown to increase
with normal ageing in healthy individuals [12]. The upper normal reference limits of CSF NFL
previously established using CSF samples from 108 neurologically healthy control individuals
were<380 ng/l (18–29 years),<560 (30–39 years),<890 (40–59 years),<1850 (>59 years).
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CSF neopterin was analyzed using a commercially available immunoassay (BRAHMS, Berlin,
Germany), with an upper normal reference value of 5.8 nmol/l [22].
Statistical analysis
Descriptive statistics were performed using Prism (version 6, Graph-Pad) or SPSS (IBM SPSS
version 20) software. Continuous variables were log10 transformed where appropriate for the
tests used. For comparisons of continuous variables between independent groups, the Mann-
Whitney test or T-test was used, as appropriate. Comparisons of categorical variables were ana-
lyzed using Fishers exact test or χ2-test. Correlations were explored using Pearson correlation.
Analyses involving repeated measurements were performed with linear mixed effects models.
Results
Study population
Ninety-nine subjects (90% male) who fulfilled inclusion criteria were identified from the
HNRP studies and included in the analysis. Twenty-nine subjects were classified as NCN and
70 as NCI (37 with ANI and 33 with MND). The median (IQR) interval between visits for the
whole study population was 249 (182–366) days. Subject baseline characteristics of the two
groups are shown in Table 1.
All subjects were on combination ART with plasma HIV-1 RNA<50 copies/ml at baseline.
All but one subject (CSF HIV-1 RNA 52 copies/ml) also had a baseline HIV-1 RNA<50
Table 1.
Baseline characteristics
Subject group NPN (n = 29) NCI (n = 70) p Value
GDS, median (IQR) 0.067 (0–0.26) 0.87 (0.66–1.41) -
Age 45 (39–53) 48 (42–55)
Male sex (%) 26/29 (90%) 64/70 (91%)
Ethnicity
White (%) 21 (72%) 49 (70%)
Hispanic (%) 3 (10%) 7 (10%)
African American (%) 3 (10%) 11 (16%)
Nadir CD4, median (IQR) cells/mm3 120 (10–274) 64 (10–206)
Current CD4, median (IQR) cells/mm3 602 (453–899) 503 (334–685) 0.04
CSF WBC 2 (1–3) 1 (1–2)
Undetectable in plasma, median (IQR) days 783 (354–1689) 382 (0–1084) 0.02
Undetectable in CSF, median (IQR) days 455 (188–1085) 363 (0–600)
Lifetime major depression, n (%) 14/26 (54%) 39/66 (59%)
Current major depression, n (%) 2/25 (8%) 7/65 (11%)
Time between visits, median (IQR) 329 (177–370) 241 (183–364)
ART regimen
NNRTI + NRTIs 12 (41%) 24 (34%)
PI+/-r + NRTIs 11 (38%) 31 (44%)
INSTI + NRTIs 0 2 (3%)
Other* 6 (21%) 13 (19%)
NPN, neurocognitive performance normal; NCI, neurocognitively impaired; GDS, global deﬁcit score; IQR, interquartile range; CSF, cerebrospinal ﬂuid;
WBC, white blood cell count; ART, antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleos(t)ide reverse transcriptase
inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor.
* including PI+NNRTI+NRTIs; NNRTI+INSTI+NRTIs; PI+INSTI+NRTIs
doi:10.1371/journal.pone.0157160.t001
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copies/ml in CSF. ART regimens were similar in the two patient groups (Table 1). By study
design, the median (IQR) GDS was higher in the NCI group (0.87 [0.63–1.4]) than in the NCN
group (0.067 [0–0.26]). Current CD4+ T- cell count was high in both groups, although statisti-
cally significantly lower in the NCI subject group at baseline (Table 1), but not at follow up. At
follow up, median (IQR) CD4+ T-cell count was 514 (349–776) cells/mm3 in the NCI group,
and 640 (418–941) cells/mm3 in the NCN group (p = 0.12). Additionally, the NCN group had
a longer history of viral suppression in plasma than the NCI group (Table 1). Although subjects
in the NCI group tended to have a lower nadir CD4+ T-cell count than the unimpaired subject
group, this difference was not statistically significant. The rate of major depression, either life-
time or current, did not differ in the two subject groups.
At follow up, three patients had detectable HIV-1 RNA in plasma (75, 76 and 184 copies/
ml), two in CSF (59 and 925 copies/ml) and one patient had detectable HIV-1 RNA in both
plasma and CSF (106 and 74 copies/ml, respectively), all in the NCI group. All subjects with
detectable CSF HIV-1 RNA had CSF neopterin above the upper normal reference value at fol-
low up (range 15.1–60 nmol/l). However, none of the subjects with viral RNA above detection
level in either plasma or CSF had CSF NFL above the upper normal age-adjusted reference.
CSF biomarkers and neurocognitive impairment
An overview of the distribution of CSF biomarkers at baseline and follow up in the study
groups is shown in Fig 1. Baseline median (IQR) CSF NFL levels were 577 (371–769) ng/l in
the NCI group and 462 (364–552) ng/l in the NCN group. At follow up, corresponding levels
were 561 (385–746) and 435 (375–535) ng/l, respectively.
Fig 2 shows the relationship between NFL and neurocognitive status in the study subjects.
Although the difference corresponded to 18% higher geometric mean CSF NFL levels in the NCI
group, this was not statistically significant in linear mixed effects model analysis (p = 0.12). More-
over, CSF NFL increases with normal ageing, and after adding age as a covariate in the model, the
corresponding difference in CSF NFL levels between study groups was 12% (p = 0.27).
CSF neopterin levels were higher in the NCI group. Baseline median (IQR) neopterin was
7.2 (4.9–10.9) nmol/l in the NCI-group, and 4.8 (4.7–7.4) nmol/l in the NCN group. At follow
up, neopterin in the NCI and NCN groups was 6.3 (4.8–10.2) and 4.9 (4.6–7.2) nmol/l, respec-
tively. In linear mixed model analysis of log10 CSF neopterin, this difference corresponded to
25% higher geometric mean CSF neopterin levels in the NCI group (p = 0.04) (Fig 3).
Using the previously defined age-related laboratory cut-off levels for CSF NFL, 13/70 (19%)
patients in the NCI group had NFL above the upper normal age-related reference in at least
one sample, compared to only one (1/29; 3%) patient in the NCN group (p = 0.06). For CSF
neopterin, 46/70 (66%) in the NCI group compared to 12/28 (43%) in the NCN group had
neopterin above the upper normal reference of 5.8 nmol/l on at least one occasion (p = 0.04).
CSF NFL was significantly correlated to CSF neopterin in the NCI group (r = 0.30;
p = 0.0003), whereas no correlation between the biomarkers was seen in the NCN group (r =
-0.13; p = 0.3). Additional weak correlations found between CSF NFL or neopterin and other
factors (current or nadir CD4+ T-cell count, time undetectable in plasma) did not remain sig-
nificant predictors of either biomarker in multivariate analysis. Although the time between vis-
its varied in the study population, no correlation was found between time between visits and
change in CSF NFL or CSF neopterin.
CSF biomarkers and progression of impairment
Overall, 32 subjects within the NCI group experienced a NP-decline from baseline to follow
up, while 38 subjects remained stable. No significant difference in CSF NFL was seen between
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NCI-stable or NCI-decline subjects (p = 0.5) (Fig 2). Median (IQR) CSF NFL at baseline was
580 (374–798) ng/l in NCI-stable and 555 (347–744) ng/l in NCI-decline subjects. At follow
up, corresponding CSF NFL was 586 (409–786) and 536 (320–735) ng/l, respectively. Addi-
tionally, no significant difference was found in the proportion of patients with abnormal age-
adjusted CSF NFL in the subjects with NCI decline (4/32) compared to NCI-stable patients (9/
38) (p = 0.4)
Median (IQR) baseline CSF neopterin was 7.0 (4.9–9.4) nmol/l in NCI-stable and 7.7 (4.9–
13.0) in NCI-decline subjects. Corresponding CSF neopterin at follow up was 6.1 (4.8–9.3) and
6.3 (4.9–13.6) nmol/l, respectively. Although geometric mean CSF neopterin was 21% higher
in NCI-decline patients, this difference did not reach statistical significance (p = 0.1) (Fig 3).
Furthermore, we found no significant difference in the proportion of abnormal CSF neopterin
in patients with NCI-decline (12/32) compared to NCI-stable patients (12/38) (p = 0.6).
Fig 1. Overview of CSF biomarker distribution in the study groups. Baseline and follow up distribution of CSF
NFL (A.) and neopterin (B.) in neurocognitively normal (NCN) and neurocognitively impaired (NCI) subjects.
Whiskers show 10-90th percentile. Values are log10 transformed for presentation. Dotted line represents upper
normal reference for CSF neopterin (5.8 nmol/l).
doi:10.1371/journal.pone.0157160.g001
Fig 2. CSF NFL in relation to neurocognitive status and longitudinal stability.CSF NFL at baseline (x-
axis) and follow up (y-axis) in neurocognitively normal (NCN) and neurocognitively impaired (NCI) patients
(stratified by stability of neurocognitive performance (NP) as NP-stable or NP-decline). Individuals are
represented by circles (NFL within age-adjusted normal limits) or triangles (abnormal age-adjusted NFL) and
group medians by solid lines. Change in NFL between visits is represented by the distance from the diagonal.
Geometric mean CSF NFL was non-significantly higher in neurocognitively impaired (NCI) patients,
demonstrated by the difference between the medians (linear mixed effects model; p = 0.27). The proportion of
above-normal (triangles) to normal (circles) CSF NFL was higher in NCI patients (19%) than in NCN patients
(1%) (Fishers exact test; p = 0.06). CSF NFL in relation to neurocognitive stability was analyzed in the NCI
group, where 32/70 patients had a NP-decline (red) and 38 patients were NP-stable (yellow). No difference in
CSF NFL was seen between NCI stable and NCI decline subjects, illustrated by the narrow distance between
the medians (linear mixed effects model; p = 0.5). Overall, there was no significant change from baseline to
follow up in CSF NFL in the treatment groups, demonstrated by the symmetry around the diagonal.
doi:10.1371/journal.pone.0157160.g002
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Discussion
The clinical and pathological importance of the milder HAND forms (particularly ANI) has
been questioned in patients responding well to ART. In the present study of effectively treated,
virally suppressed HIV-1 infected patients, we demonstrate that patients with milder forms of
HAND (ANI and MND) had a higher degree of intrathecal immune activation than patients
without neurocognitive impairment, suggesting that even the milder forms of HANDmay rep-
resent a clinically significant pathologic process within the CNS. Moreover, the correlation
between CSF NFL and neopterin found in the NCI patient group, but not in the NCN group,
indicates a mechanistic association between CNS inflammation, neuronal damage and neuro-
cognitive impairment during effective ART.
In patients with HIV-associated dementia, the most severe form of HAND, HIV-1 infection
in the CNS initiates a neuropathological inflammatory response known as HIV encephalitis
(HIVE). HIVE is characterized by immune activation and neuronal damage that is measurable
in the CSF of patients with HIV-associated dementia [6, 11, 12, 23, 24]. However, the patho-
genesis of the milder HAND forms prevalent during effective antiretroviral therapy is less
clear, and may differ from that of more severe HAND [25].
Previous studies have shown substantially increased levels of CSF NFL in patients with
HAD, and mild elevations in some untreated neurologically asymptomatic patients, mainly
with low CD4+ T-cell counts [11, 12]. However, CSF NFL is frequently normalized after
Fig 3. CSF neopterin in relation to neurocognitive status and longitudinal stability. CSF neopterin at
baseline (x-axis) and follow up (y-axis) in neurocognitively normal (NCN) and neurocognitively impaired (NCI)
patients (stratified by stability of neurocognitive performance (NP) as NP-stable or NP-decline). Individuals
are represented by circles and group medians by solid lines. Change in neopterin between visits is
represented by the distance from the diagonal. Geometric mean CSF neopterin was significantly higher in
neurocognitively impaired (NCI) patients than in neurocognitively normal (NCN) patients, as indicated by the
distance between the medians (linear mixed effects model; p = 0.036). The upper normal reference for CSF
neopterin is represented by the dotted line, and the proportion of patients with CSF neopterin above the upper
normal reference was significantly higher in NCI patients (66%) than in NCN patients (43%) (Fishers exact
test; p = 0.04). CSF neopterin was non-significantly higher in the NCI-decline group, compared to the NCI-
stable group (linear mixed effects model; p = 0.1).
doi:10.1371/journal.pone.0157160.g003
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initiation of ART, although a low level elevation within the normal range has been detected in
virally suppressed patients when compared to HIV-negative healthy controls [12, 26]. In the
current analysis, we did not see any statistically significant difference in age-adjusted CSF NFL
between the two study groups, although the study may have been underpowered to detect a
low level difference in CSF NFL. Moreover, the majority of subjects had CSF NFL within the
normal range, although the proportion of patients with abnormal CSF NFL levels was higher
in the NCI group with a trend seen towards significance (p = 0.06). The frequency of abnormal
NFL in the NCI group was 20%, which is substantially higher than numbers reported in previ-
ous studies of virally suppressed patients [12, 27]. In the NCN group, the number of patients
with CSF NFL within the normal range (97%) was comparable to numbers previously found in
HIV-negative healthy controls [12]. Additionally, the correlation found between CSF NFL and
neopterin in the NCI group, has previously only been reported in untreated patients but not in
patients with effective ART [12]. No correlation between the biomarkers was seen in the unim-
paired subject group, suggesting that neurocognitive impairment might reflect a discrete, con-
tinuous neuroinflammation and axonal degradation at least in some individuals, despite
otherwise effective ART.
The higher levels of CSF neopterin found in subjects with NCI in the current analysis sug-
gest that even the milder forms of HANDmay result from an ongoing pathological process
within the CNS. However, we found no clear biomarker evidence of a link between neuroin-
flammation and neurocognitive decline. All of the NCN subjects in the study were stable in
neurocognitive performance, including only NCI subjects in the evaluation of CSF biomarkers
in relation to neurocognitive decline. Although neopterin tended to be higher in subjects with
baseline impairment and NP-decline, this difference was non-significant (p = 0.1). Neopterin
is a sensitive marker of macrophage and microglial activation, and almost all of the neopterin
detected in CSF originates from inside the CNS [28]. Although ART greatly reduces intrathecal
immune activation, CSF neopterin remains elevated in a significant proportion of patients
despite viral suppression [13]. Whether this residual intrathecal immune activation results
from persistent low level viral replication within the CNS despite apparently effective ART or
from other causes remains unclear. Using sensitive assays, patients with detectable low-level
residual CSF virus had higher neopterin levels than subjects with undetectable HIV-1 RNA in
CSF, indicating that elevated CSF neopterin is intimately correlated to CSF viral load [29, 30].
Although all but one subject included in the current analysis had CSF HIV-1 RNA below the
detection level of 50 copies/ml in routine clinical PCR assays at baseline, we cannot rule out a
difference between subject groups in low-level CSF viral load if more sensitive assays had been
used, and that such differences could have a potential influence on intrathecal immune activa-
tion. Additionally, we cannot rule out that differences in ART adherence may have influenced
results. Although only six subjects had detectable virus in plasma or CSF at follow up, all were
in the NCI group.
The currently used diagnostic criteria of HAND have been criticized for overestimating the
prevalence of impairment in patients on ART, thereby obscuring identification of the actual
burden of HIV-related brain disease and that milder forms of HAND (mainly ANI) may have
little clinical significance [15, 16]. The use of neuropsychological testing in relation to norma-
tive controls in the diagnosis of HAND does not differentiate between ongoing brain injury
and static residual damage, such as residual sequele after injuries related to advanced disease
with a low CD4+ T-cell count prior to initiation of ART. Although the NCI group in the pres-
ent study had increased immune activation as a reflection of an active immunologic process,
we did not find a significant relationship between decline in neurocognitive performance and
the CSF biomarkers measured in this study, indicating that effective ART may be sufficient in
limiting CNS damage in most patients. However, recent data suggest an increased risk for
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progression to symptomatic HAND in individuals with ANI [17]. Although not all patients in
the report by Grant et al. were on effective ART, a sub analysis did not reveal different results
in the virally suppressed subjects, suggesting that in some individuals, the presence of a HAND
diagnosis may represent a risk of progression in neurocognitive impairment despite effective
ART.
In this study, all subjects were using effective, virally suppressive combination ART, and
individuals with known significant comorbid conditions that could influence either NP-test
result or CSF biomarkers were excluded. However, we cannot rule out the presence of back-
ground factors such as prior drug use, abdominal obesity or other components of the metabolic
syndrome[31] or other differences between the study groups (unknown or not recorded)
which may have influenced the findings. Additionally, the time between study visits may not
have been sufficient to detect a difference in CSF biomarkers in relation to the stability of neu-
rocognitive performance although we did not detect any differences in biomarkers in the
included subjects that had a NP decline.
Conclusions
The findings in this study indicate that milder HAND forms may be a clinically significant
reflection of an ongoing pathologic process within the CNS in some patients, where viral sup-
pression alone is not sufficient to eliminate neuronal inflammation. The correlation found
between CSF neopterin and NFL in subjects with neurocognitive impairment also indicates a
mechanistic association between immune activation, neuronal damage and neurocognitive
impairment during effective ART. Although standard ART is likely sufficient to prevent neuro-
logic complications in most patients, effective control of viral replication through ART alone
may not be sufficient in all cases. Methods of identifying individual patients at risk of develop-
ing, as well as progressing in HAND are needed, where the use of CSF biomarkers and neuro-
psychological testing will likely continue to be important tools.
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Seattle, Washington University, St. Louis and is headquartered at the University of California,
San Diego and includes: Director: Igor Grant, M.D.; Co-Directors: J. Allen McCutchan, M.D.,
Ronald J. Ellis, M.D., Ph.D., Thomas D. Marcotte, Ph.D.; Center Manager: Donald Franklin,
Jr.; Neuromedical Component: Ronald J. Ellis, M.D., Ph.D. (P.I.), J. Allen McCutchan, M.D.,
Terry Alexander, R.N.; Laboratory, Pharmacology and Immunology Component: Scott
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Letendre, M.D. (P.I.), Edmund Capparelli, Pharm.D.; Neurobehavioral Component: Robert K.
Heaton, Ph.D. (P.I.), J. Hampton Atkinson, M.D., Steven Paul Woods, Psy.D., Matthew Daw-
son; Virology Component: David Smith, M.D. (P.I.); Imaging Component: Christine Fen-
nema-Notestine, Ph.D. (P.I.), Terry L. Jernigan, Ph.D., Michael J. Taylor, Ph.D., Rebecca J.
Theilmann, Ph.D., John Hesselink, M.D.; Data Management Unit: Anthony C. Gamst, Ph.D.
(P.I.), Clint Cushman; Statistics Unit: Ian Abramson, Ph.D. (P.I.), Florin Vaida, Ph.D.; Protocol
Coordinating Component: Thomas D. Marcotte, Ph.D. (P.I.); Johns Hopkins University Site:
Justin McArthur (P.I.), Mary Smith; Icahn School of Medicine at Mount Sinai Site: Susan Mor-
gello, M.D. (Co-P.I.) and David Simpson, M.D. (Co-P.I.), Letty Mintz, N.P., Cheuk Tang, Ph.
D., and Thomas Naidich, M.D.; University of California, San Diego Site: J. Allen McCutchan,
M.D. (P.I.), Will Toperoff, N.P.; University of Washington, Seattle Site: Ann Collier, M.D. (Co-
P.I.) and Christina Marra, M.D. (Co-P.I.), Kenneth Maravilla, MD, KC Stegbauer, Ph.D.,
Trudy Jones, M.N., A.R.N.P.; University of Texas, Galveston Site: Benjamin Gelman, M.D., Ph.
D. (P.I.), Eleanor Head, R.N., B.S.N., Gregory Chaljub, M.D.; andWashington University,
St. Louis Site: David Clifford, M.D. (P.I.), Muhammad Al-Lozi, M.D., Mengesha Teshome, M.D.
Author Contributions
Conceived and designed the experiments: MG RWP. Performed the experiments: D. Fuchs
HZ. Analyzed the data: AE MG SN. Wrote the paper: AE TDM RKH SN HZ D. Fuchs D.
Franklin RWP IG SLL MG. Designed, performed, and coordinated the parent study (CHAR-
TER) as well as the substudy (the NIMH AIDS Research Center (ARC) Biomarker project): IG
RKH SLL TDM D. Franklin. Reviewed and identified the cases for the project: SLL TDMD.
Franklin.
References
1. Lescure FX, Omland LH, Engsig FN, Roed C, Gerstoft J, Pialoux G, et al. Incidence and impact on mor-
tality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide
cohort study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of
America. 2011; 52(2):235–43. doi: 10.1093/cid/ciq041 PMID: 21288850.
2. Heaton RK, Clifford DB, Franklin DR Jr., Woods SP, Ake C, Vaida F, et al. HIV-associated neurocogni-
tive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010; 75
(23):2087–96. doi: 10.1212/WNL.0b013e318200d727 PMID: 21135382; PubMed Central PMCID:
PMC2995535.
3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for
HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789–99. doi: 10.1212/01.WNL.
0000287431.88658.8b PMID: 17914061.
4. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dys-
function in HIV patients despite long-standing suppression of viremia. AIDS (London, England). 2010;
24(9):1243–50. doi: 10.1097/QAD.0b013e3283354a7b PMID: 19996937.
5. Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the
context of plasma HIV RNA suppression. Journal of neurovirology. 2011; 17(2):176–83. doi: 10.1007/
s13365-011-0021-x PMID: 21416169.
6. GisslenM, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, et al. Defining and evaluating HIV-
related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospi-
nal fluid molecular biomarkers. Journal of neuroimmune pharmacology: the official journal of the Society on
NeuroImmune Pharmacology. 2007; 2(1):112–9. doi: 10.1007/s11481-006-9035-1 PMID: 18040834.
7. Price RW, Epstein LG, Becker JT, Cinque P, Gisslen M, Pulliam L, et al. Biomarkers of HIV-1 CNS
infection and injury. Neurology. 2007; 69(18):1781–8. doi: 10.1212/01.wnl.0000278457.55877.eb
PMID: 17967994.
8. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain
Res. 2003; 987(1):25–31. PMID: 14499942.
9. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral
sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF.
Journal of neurochemistry. 1996; 67(5):2013–8. PMID: 8863508.
Increased Immune Activation in HIV-1 Patients with HAND
PLOSONE | DOI:10.1371/journal.pone.0157160 June 13, 2016 11 / 13
10. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are
increased in dementia. Neurology. 1999; 52(5):1090–3. PMID: 10102440.
11. Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, et al. CSF neurofilament protein
(NFL)—a marker of active HIV-related neurodegeneration. Journal of neurology. 2007. PMID:
17420923.
12. Jessen Krut J, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, et al. Biomarker evidence of
axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014; 9(2):e88591. doi: 10.1371/
journal.pone.0088591 PMID: 24523921; PubMed Central PMCID: PMC3921217.
13. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Immune activation of the central ner-
vous system is still present after >4 years of effective highly active antiretroviral therapy. The Journal of
infectious diseases. 2007; 196(12):1779–83. Epub 2008/01/15. doi: 10.1086/523648 PMID: 18190258.
14. Yilmaz A, Yiannoutsos CT, Fuchs D, Price RW, Crozier K, Hagberg L, et al. Cerebrospinal fluid neop-
terin decay characteristics after initiation of antiretroviral therapy. Journal of neuroinflammation. 2013;
10:62. doi: 10.1186/1742-2094-10-62 PMID: 23664008; PubMed Central PMCID: PMC3657550.
15. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we
overestimating the real prevalence? BMC infectious diseases. 2011; 11:356. doi: 10.1186/1471-2334-
11-356 PMID: 22204557; PubMed Central PMCID: PMC3260107.
16. Torti C, Foca E, Cesana BM, Lescure FX. Asymptomatic neurocognitive disorders in patients infected
by HIV: fact or fiction? BMCmedicine. 2011; 9:138. doi: 10.1186/1741-7015-9-138 PMID: 22204606;
PubMed Central PMCID: PMC3273440.
17. Grant I, Franklin DR Jr., Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated
neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014; 82(23):2055–62.
doi: 10.1212/WNL.0000000000000492 PMID: 24814848; PubMed Central PMCID: PMC4118496.
18. Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al. Defining neurocognitive
impairment in HIV: deficit scores versus clinical ratings. The Clinical neuropsychologist. 2012; 26
(6):894–908. doi: 10.1080/13854046.2012.694479 PMID: 22708483; PubMed Central PMCID:
PMC3848322.
19. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, et al. Predictive validity of global
deficit scores in detecting neuropsychological impairment in HIV infection. Journal of clinical and exper-
imental neuropsychology. 2004; 26(3):307–19. doi: 10.1080/13803390490510031 PMID: 15512922.
20. Cysique LA, Franklin D Jr., Abramson I, Ellis RJ, Letendre S, Collier A, et al. Normative data and valida-
tion of a regression based summary score for assessing meaningful neuropsychological change. Jour-
nal of clinical and experimental neuropsychology. 2011; 33(5):505–22. doi: 10.1080/13803395.2010.
535504 PMID: 21391011; PubMed Central PMCID: PMC3151558.
21. Heaton RK, Franklin DR Jr., Deutsch R, Letendre SL, Ellis RJ, Casaletto K, et al. Neurocognitive
change in the era of HIV combination antiretroviral therapy: A longitudinal CHARTER Study. Clinical
infectious diseases: an official publication of the Infectious Diseases Society of America. 2014. doi: 10.
1093/cid/ciu862 PMID: 25362201.
22. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, et al. Cerebrospinal fluid neopterin:
an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS
research and therapy. 2010; 7:15. doi: 10.1186/1742-6405-7-15 PMID: 20525234; PubMed Central
PMCID: PMC2890504.
23. Krut JJ, Zetterberg H, Blennow K, Cinque P, Hagberg L, Price RW, et al. Cerebrospinal fluid Alzhei-
mer's biomarker profiles in CNS infections. Journal of neurology. 2013; 260(2):620–6. doi: 10.1007/
s00415-012-6688-y PMID: 23052602.
24. Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell
count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. The Journal of
infectious diseases. 1996; 174(2):294–8. PMID: 8699058.
25. Gelman BB, Chen T, Lisinicchia JG, Soukup VM, Carmical JR, Starkey JM, et al. The National Neu-
roAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment.
PLoS One. 2012; 7(9):e46178. doi: 10.1371/journal.pone.0046178 PMID: 23049970; PubMed Central
PMCID: PMC3458860.
26. Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, Gisslen M. Antiretroviral treatment reduces
increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology. 2007; 69(15):1536–41. doi:
10.1212/01.wnl.0000277635.05973.55 PMID: 17923616.
27. Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, et al. Cerebrospinal fluid
(CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.
PLoS One. 2014; 9(12):e116081. doi: 10.1371/journal.pone.0116081 PMID: 25541953; PubMed Cen-
tral PMCID: PMC4277428.
Increased Immune Activation in HIV-1 Patients with HAND
PLOSONE | DOI:10.1371/journal.pone.0157160 June 13, 2016 12 / 13
28. Bogner JR, Junge-Hulsing B, Kronawitter U, Sadri I, Matuschke A, Goebel FD. Expansion of neopterin
and beta 2-microglobulin in cerebrospinal fluid reaches maximum levels early and late in the course of
human immunodeficiency virus infection. The Clinical investigator. 1992; 70(8):665–9. PMID: 1392442.
29. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Persistent intrathecal immune activa-
tion in HIV-1-infected individuals on antiretroviral therapy. Journal of acquired immune deficiency syn-
dromes (1999). 2008; 47(2):168–73. doi: 10.1097/QAI.0b013e31815ace97 PMID: 17971711; PubMed
Central PMCID: PMC2628632.
30. Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW. Low levels of HIV-1 RNA detected in the
cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activa-
tion. AIDS (London, England). 2014; 28(15):2251–8. doi: 10.1097/QAD.0000000000000400 PMID:
25022595.
31. Sattler FR, He J, Letendre S, Wilson C, Sanders C, Heaton R, et al. Abdominal obesity contributes to
neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation.
Journal of acquired immune deficiency syndromes (1999). 2015; 68(3):281–8. doi: 10.1097/QAI.
0000000000000458 PMID: 25469522; PubMed Central PMCID: PMC4551458.
Increased Immune Activation in HIV-1 Patients with HAND
PLOSONE | DOI:10.1371/journal.pone.0157160 June 13, 2016 13 / 13
